Clover Health (CLOV) Wins Lawsuit on Star Ratings, Soars to Record High

Clover Health (CLOV) shares rose 9.3% in the afternoon after Canaccord Genuity raised its price target to $4.20 from $3.20 and kept a Buy rating, citing progress in its 2026 managed-care thesis. The article notes CLOV’s high volatility and recent strong results, including Q1 2026 EPS of $0.05 and revenue of $749.2 million.

On Thursday, 11 stocks with market caps above $2B and at least 5M shares traded posted double-digit gains, helping all three US indices finish higher (Nasdaq +0.91%, S&P 500 +0.58%, Dow +0.05%). Infleqtion rose 14.94% on plans to triple UK capacity; Best Buy gained 15.80% after Q1 fiscal 2027 results and guidance; Clover Health jumped 16.43% after a court order tied to 2026 star ratings; Agilent rose on Q2 earnings and raised outlook; Dollar Tree climbed 17.87% on Q1 revenue and sales growth.

Analysts say AI infrastructure spending is outpacing revenue. The report estimates the sector would need about $650B a year to earn a 10% return on current capex, versus roughly $25B in revenue run-rates. Big tech hyperscalers are projected to spend ~$725B by 2026. Regulators, including the Federal Reserve, cite AI as a top systemic risk.

Clover Health's interim CFO, Joseph Clay, had 16,942 Class A shares automatically withheld at $3.47 per share on May 16, 2026, to cover tax obligations from RSU vesting. This tax withholding represents 6.25% of his original RSU grant from February 2024, with remaining RSUs vesting quarterly until February 2028, subject to continued service. Following this transaction, Clay directly holds 1,217,584 Class A shares.

Joseph Frank Oldakowski, VP of Finance and Controller at Clover Health Investments, Corp. (CLOV), has filed an initial ownership report (Form 3) disclosing beneficial ownership of 311,169 shares of Class A common stock. These shares are part of unvested time-based restricted stock units granted on June 16, 2025, and December 19, 2025, and represent equity-based compensation rather than open-market transactions. The filing clarifies that this is an initial statement of ownership, not a buy or sell transaction.

Clover Health Investments (CLOV) has granted its Chief Legal Officer, Karen Soares, 382,522 Restricted Stock Units (RSUs) of Class A common stock. These RSUs were awarded at no cash cost, increasing her direct ownership to 1,582,583 shares. The vesting schedule dictates that 25% will vest on April 1, 2027, with the remainder vesting in quarterly installments until April 1, 2030, contingent on her continued employment.